Showing results (201-210 of 253) with videos related to

Sort By:
Pageof 26
Alimentary Pharmacology & Therapeutics|March 3, 2015
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysisJ-F Colombel, W Reinisch, G J Mantzaris, et al.
Gastroenterology|June 2, 2000
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapyJ F Colombel, N Ferrari, H Debuysere, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2016
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapyJ-F Colombel, B Jharap, W J Sandborn, et al.
Gut|November 22, 2005
Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammationD Philippe, D Chakass, X Thuru, et al.
Alimentary Pharmacology & Therapeutics|November 24, 2012
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2W J Sandborn, J-F Colombel, G D'Haens, et al.
The Journal of Experimental Medicine|April 3, 2001
Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategiesP Desreumaux, L Dubuquoy, S Nutten, et al.
Alimentary Pharmacology & Therapeutics|January 24, 2017
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensusL Vuitton, L Peyrin-Biroulet, J F Colombel, et al.
Mucosal Immunology|July 16, 2015
The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophilsV Driss, M El Nady, M Delbeke, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2017
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trialX Roblin, G Boschetti, N Williet, et al.
Alimentary Pharmacology & Therapeutics|October 1, 1996
Treatment of severe Crohn's disease with anti-CD4 monoclonal antibodyV Canva-Delcambre, S Jacquot, E Robinet, et al.
Pageof 26